Methods of amorphization and investigation of the amorphous state by TOMAŽ EINFALT et al.
The existence of drugs and excipients in multiple physical forms (e.g., polymorphs)
provides pharmaceutical scientists with an opportunity to select the preferred form of
the material to be used in a formulation. This is very useful since critical properties, such
as particle morphology and dissolution properties, are frequently different in the differ-
ent physical forms of a material. The amorphous form of pharmacologically active mate-
rials has received considerable attention because, in theory, it represents the most ener-
getic solid state of a material, and should thus provide the biggest advantages in terms
of dissolution rate and bioavailability (1). However, the amorphous form also shows
various disadvantages, such as lower physical stability compared to crystals.
The structure of an amorphous solid is usually described as possessing a crystal-
-like short-range molecular arrangement, but lacking a long-range order. As illustrated
by Fig. 1, the immediate environment of a molecule (m) in an amorphous solid may not
differ significantly from that in a crystal (e.g., similar number of and distance to nearest
neighbors), but an amorphous solid lacks any long-range transational-orientational sym-
metry that characterizes a crystal (1). However, this is only true when we are dealing
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with non-ionic material and substances that do not form strong intermolecular connec-
tions with water.
In Fig. 2, the enthalpy (H) or specific volume (V) of a solid substance is plotted as a
function of temperature. For crystalline material, at very low temperatures we see a
small increase in enthalpy and volume with respect to temperature, which is indicative
of a certain heat capacity (Cp) and thermal expansion coefficient. There is a discontinuity
in both H and V at the melting temperature Tm representing the first order phase transi-
tion to the liquid state. Upon rapid cooling of the melt, the values of H and V may follow
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Fig. 1. Schematic representation of the structure of an amorphous and a crystalline solid. Molecular
arrangement in the amorphous solid is not totally random, like in the gas phase, but features a
short-range molecular order similar to that in the crystalline one. According to some models, an
amorphous solid has distinct regions (e.g., a and b), which have different densities and thermal re-
laxation behaviors (i.e., the time scale for long-range molecular motion). Adapted from ref. 2 with
permission.
Fig. 2. Schematic description of the variation in enthalpy (or volume) with temperature Tm, Tg,Tk.
Adapted from ref. 1 with permission.
the equilibrium line for the liquid beyond the melting temperature into a »super-cooled
liquid« region. On further cooling, a change in slope is usually seen at the characteristic
temperature known as the glass transition temperature (Tg). At Tg, the properties of the
glassy material deviate from those of the equilibrium super-cooled liquid to give a
non-equilibrium state having even higher H and V than the super-cooled liquid. The
Kauzmann temperature (Tk) is thought to mark the lower limit of the experimental glass
transition (Tg) (1).
Amorphous materials have higher Gibbs free energy than their crystalline counter-
parts, and as a result have higher apparent solubility and faster dissolution rates, which
in turn can lead to higher bioavailability for drugs that exhibit dissolution-rate limited
absorption (classified according to the Biopharmaceutical Classification System (BSC) as
class II drugs) (3). However, due to excess entropy, enthalpy and free energy that ac-
count for better solubility, the amorphous state is inherently unstable and recrystalliza-
tion may occur (2).
METHODS OF AMORPHIZATION
The most common techniques of preparing amorphous forms in pharmaceutical
systems (e.g., pure drugs or polymer glass solutions) can be categorized according to
two principal transformation mechanisms. In most cases, crystalline material is interme-
diately transformed into a thermodynamically unstable non-crystalline form (either a
melt or a solution). Further, the thermodynamically unstable amorphous solid material
is prepared by quench cooling of the melt or rapid precipitation from solution, e.g.,
spray drying. The other transformation mechanism involves direct solid conversion
from the crystalline to the amorphous form. The best example is mechanical activation
such as milling. Whilst when melt and solution mediated methods are used all crystalli-
nity is lost in the intermediate phase (melt, solution), mechanical activation methods
may not cause complete disruption of the molecular order (1, 4–6).
It should also be noted that differently prepared amorphous form exhibits different
properties. Salvonien et al. (7) have found that the cryo-milled simvastatin has lower sta-
bility and a reduced recrystallization rate than quench cooled samples of the same sub-
stance. In comparison, Karmwar et al. (8) found that the cryo-milled amorphous form of
indomethacin is the least stable compared to amorphous form prepared by quench cool-
ing and spray drying. Moreover, it should be noted, the differences between the differ-
ently prepared amorphous forms are not only in the stability but can be detected on the
molecular level using terahertz spectroscopy or solid state NMR (ss-NMR) (9, 10).
The term polyamorphism has been used to describe amorphous states produced by
different annealing times or preparative routes. An example are glasses that have been
aged below Tg for different times and hence developed various degrees of »relaxation
enthalpy«, that is, the enthalpy of an aged amorphous substance (2). The term poly-
amorphism has also been used in literature to describe the existence of distinct amor-
phous phases separated by first-order phase transitions (4, 11). Patterson et al. (12) have
shown that the susceptibility to amorphous conversion by different methods is com-
pound specific. Therefore if amorphous conversion is required, there is merit in investi-
gating the use of more than one preparative technique.
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Besides the possibility of the existence of polyamorphs for pharmaceutically rele-
vant substances, the concept of a rigid amorphous fraction (RAF) has also been intro-
duced. RAF is believed to be an intermediate between the crystalline and amorphous
phases. The striking difference between RAF and the »true« amorphous fraction lies in
the change of heat capacity (DCp) at the glass transition (Tg). As RAF is more closely as-
sociated with the crystalline state, it does not undergo a change in Cp and Tg. This im-
plies that an amorphous form containing RAF will exhibit a smaller change in Cp and Tp
than the same amorphous substance without RAF (13). Solid-state amorphization will
be the main topic addressed in this paper.
Solution based methods of amorphization
Melting and quench cooling. – Melting and quench cooling of a crystalline drug to
produce an amorphous product is a relatively simple technique. Upon cooling of the
molten drug below the freezing point, molecular motion is slowed down. If cooling of
the molten drug takes place fast enough, the molecules are not able to rearrange into a
crystalline lattice; therefore, they are »frozen« in a more disordered state and crystalliza-
tion is avoided (14, 15). The slower a liquid is cooled, the longer is the time available for
configurational sampling at each temperature, and the colder it can become before fall-
ing out of liquid (7). Therefore the enthalpy of the end product depends on the cooling
rate (16) although it must be noted that if the cooling rate is too slow, the product will
crystallize. The drawback of this approach is its potential for chemical degradation dur-
ing the melting step due to high temperatures, since the degradation products may low-
er the glass transition temperature of the amorphous product (17). Thermal degradation
is compound dependent and only limited steps can be taken to overcome this problem,
such as heating under an inert gas (12). So far, a range of pharmaceutical active sub-
stances and excipients have been successfully amorphized by melting and quenching
(18–21).
Spray drying. – The spray drying technique may be suitable for obtaining the amor-
phous form of the drug substance, either alone or in combination with the polymer (22–
25). It converts a liquid solution into a powder in one step (26). Concentrated liquid is
pumped to the atomizing device where it is broken into small droplets. These droplets
meet a stream of hot air and lose the solvent very rapidly while still suspended in dry
air. Components of the concentrated liquid may not crystallize immediately when their
solubility limit is reached at the droplet surface. In this case, a fully or partially amor-
phous solid is formed (27). Drugs that have a relatively low Tg make it very difficult to
obtain a stable amorphous product in the form of free flowing powder by spray drying.
As the outlet temperature rises above the Tg, there is always a possibility that the final
product is present in the super cooled rubbery state. Also, such product is often sticky or
tacky, which causes a decrease in product recovery and hampers its handling in subse-
quent processes (22). Spray drying has been commonly used in the past decade as a
technique for preparing amorphous active substances and excipients (28–31).
Freeze-drying. – Freeze-drying, also known as lyophilization, has been used for a
number of years as a pharmaceutical unit operation for the low temperature drying of
injectable systems (32). Freeze-drying involves desiccation of a substance by crystalliza-
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tion of water, followed by sublimation of water vapor from the solid state at reduced
pressure. Depending on the cooling rate, some solutes may crystallize during the freez-
ing stage. Those solutes which do not crystallize are converted to amorphous solids
when the temperature drops below the Tg of the maximally concentrated solute. At the
end of a freeze-drying process, when the solvent is completely removed through subli-
mation, the freeze-dried formulation exists as an amorphous or partially amorphous
system. The Tg of a freeze-dried formulation is determined by components of the formu-
lation and the presence of residual water, which can act as a plasticizer lowering the
glass transition temperature (33). The process has been recently utilized to produce
amorphous trehalose and itraconazole (34, 35).
Solid state amorphization
Dehydration of crystalline hydrates. – Dehydration of crystalline hydrates has been de-
monstrated as a feasible and »gentle« route to the amorphous state of organic solids.
Saleki-Gerhardt et al. (5) showed that heating crystalline raffinose pentahydrate at 60 °C
in vacuum converts the material to an amorphous form identical to the one produced by
freeze-drying (5). Li et al. (36) observed that crystalline carbamazepine dihydrate beco-
mes amorphous upon dehydration at 45 °C with N2 purge. The resulting amorphous
solid undergoes a glass transition at 56 °C, which is markedly above the drying temper-
ature (45 °C), and crystallizes on further heating (at 86 °C). These studies indicate that
apart from being a potential route to amorphous solids, the drying of crystalline hy-
drates may reduce their physicochemical stability through loss of crystallinity. More re-
cently, Sussich et al. (37) investigated the amorphization of a di-hydrate crystalline poly-
morph of trehalose upon dehydration.
Milling. – Milling, also known as comminution or grinding, is typically regarded as
a particle size reduction process across many industries, including the manufacturing of
pharmaceuticals and fine chemicals (38, 39). In secondary pharmaceutical processing, it
is often used to increase the specific surface area of poorly water-soluble drugs to im-
prove their dissolution properties and bioavailability (40). There is a variety of different
commercially available milling equipment that can be utilized for the communition of
pharmaceuticals. In general, the devices can be subdivided into three main categories,
based on how energy is transferred to the material to be ground: ball mills, shear action
mills and shock action mills. In the case of ball mills, energy is transferred to the ground
material by mill bodies or impellers. The material is exposed to both shear and normal
stresses. On the other hand, in shear action mills, the material is ground by crushing ele-
ments (solid surfaces in relative motion). Shock action mills transfer the energy directly
to the milled material. In this case, material is milled by direct collision of particles.
However, besides reducing the particle size, the milling process is often accompanied by
other unintended effects such as changes in morphology (41), crystallinity (41), poly-
morphism (42), glass transition temperatures (43), chemical stability (44) and melting be-
havior (45) during subsequent post-milling storage. The process of milling is very en-
ergy-consuming. Furthermore, the high energy output could result in degradation of the
milled substance and the milling equipment. Milling is also used for more specific appli-
cations such as preparation of co-crystals (46, 47). Pharmaceutical literature describes
numerous examples of organic compounds like piroxicam (48), budesonide (49), sucrose
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(50, 51), lactose (52, 53), trehalose (54, 55), that become partially or completely amor-
phous when submitted to milling. However, it appears that one of the disadvantages of
amorphization through milling is that the Tg of the milled substance plays a fundamen-
tal role and sufficiently low temperatures of milling (Tmill) must therefore be provided to
induce amorphization through milling (56).
Principles of solid-state amorphization through milling. – There are several competing
ideas as to how the transformation from the crystalline to the amorphous state takes
place during milling. A commonly held view is that amorphization occurs via generation
of localized heating effects followed by quenching. Alternatively, Okamoto et al. (57)
suggest that milling leads to an increase in static disorder that adds to the intrinsic dy-
namic disorder inherent within the lattice up to critical value where the structural col-
lapse occurs. Others argue that the disordering process is best regarded as an accumula-
tion of defects (or, viewed another way, a dramatic reduction in crystallite size) and
hence may not necessarily be regarded as amorphization in the traditional sense (58).
Some of the advantages of cryogenic milling are that it is a mild method of producing
amorphous material without the use of solvents or melting.
Influence of temperature on solid-state amorphization through milling. – The group of
Descamps et al. (52, 59, 60) provides a very significant contribution on how the previ-
ously mentioned theories apply to organic crystalline materials. They have highlighted
the relationship between the temperature of milling and the glass transition temperature
of the corresponding material. In particular, they have demonstrated that cryo-milling
(well below Tg) results in amorphization and milling above Tg results in polymorphic
transformation. This contradicts the melt-quenching explanation. These authors favor
the concept of driven materials, as outlined by Martin and Bellon (61). In brief, the ap-
proach suggests that in milling a material there is a temperature independent disorder-
ing process induced by ballistic interactions, which competes with the temperature de-
pendent restoration process. The balance of these two processess is expressed in terms of
an »effective« temperature Teff, which is the temperature at which the non-milled mate-
rial would assume the same level of disorder as the milled one. A milling process that
resulted in a Teff above the melting point would therefore be expected to result in amor-
phization. The value of Teff may be estimated by Eq. (1) where T is the temperature of
milling, Dbal is the (temperature independent) ballistic diffusion coefficient and Dth is
the thermal diffusion coefficient corresponding to the restorative process.
Teff = T(1+Dball/Dth) (1)
It is significant that this theory predicts that at low temperatures Dth becomes small
compared to Dbal, hence raising Teff. This then explains the counterintuitive observation
that amorphization to a greater extent occurs at lower temperatures (62).
A related question is whether the material generated by cryo-milling behaves in a
similar manner to »conventionally« generated amorphous materials. Surprisingly, little
is known about the subject, although a thorough study by Crowley and Zografi indi-
cated that cryogenic milling of crystalline indomethacin resulted in amorphous material
with similar Tg values but reduced physical stability compared to conventionally genera-
ted amorphous indomethacin. The authors ascribed the latter to the presence of residual
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crystalline material (63). Qi et al. (62) have also demonstrated a very marked instability
of the cryo-milled material below its Tg and also the possibility of the prepared amor-
phous materials exhibiting a more complex recrystallization profile than commonly con-
sidered for the solid state amorphous form.
The effect of crystal morphology on induced crystal disorder through milling. – One persis-
tent challenge in the development of pharmaceutics is the crystal habit, or morphology.
For example, equidimensional crystals are usually preferred in the industry as they have
better handling and processing characteristics such as flowability and compactability
(64, 65). Chikalia et al. (66) have found that b-succinic acid in a plate-like morphology is
more prone to disorder than a needle-like morphology. Crystal morphology engineering
and the use of crystals with the most suitable morphology could therefore be a valuable
tool to enhance the solid-state transformation.
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Fig. 3. Indomethacin co-ground with Neusilin in different ratios at 75 % RH and stored at 40 °C/75
% RH: a) 1:1, b) 1:4, c) 1:5. Key: 12 h co-ground, – . – . – 3 days co-ground, – – – 5 days co-ground,
–––– 8 days co-ground. Adapted from ref. 78 with permission.
Co-milling. – Co-milling of drugs with excipients has been employed for accelera-
tion of solid amorphization and stabilization of amorphous state. Watanabe et al. (67)
showed that amorphization of indomethacin could be achieved by milling it with poly-
vinylpyrrolidone or silica. Ali et al. (68) used a vibration mill to prepare amorphous co-
-ground mixtures of flufenamic acid with amorphous calcium silicate and silicon-dioxide.
Amorphization of ibuprofen, sulfathiazole, phenothiazine, acridine, chloranil and vita-
min K3 has been achieved by co-grinding with polyvinylpyrrolidone (69–71). Amobar-
bital amorphized in the presence of a variety of excipients such as carbon black, ethyl
cellulose, precipitated silica and activated charcoal (72). A variety of other excipients
such as b-cyclodextrin, dextrans, chitin, chitosan, gelatin, polyethylene glycol, methyl
cellulose, hydroxyl propyl cellulose, calcium silicate and silicon dioxide were used to
amorpize structurally diverse drugs, resulting in various degrees of amorphization (67–
77). More recently, Bahl et al. (78) have shown that increasing the amount of Neusilin
US2 with respect to indomethacin reduced the amorphization time (Fig. 3). The mixture
also showed high physical stability.
Time of milling and solid state amorphization. – The crystal to glass conversion upon
milling often requires milling times of several hours to complete (50, 54). Short milling
times are thus expected to induce a size reduction of both the crystallites (small single
crystals) and the particles (a particle can be composed of several crystallites) without
generating any noticeable amorphous content. Until now, only a few investigations of
weakly milled materials have been performed and little is known about the structural
and micro-structural states that precede amorphization observed during long and inten-
se milling (79). A very important point is to determine when and how the accumulation
of crystalline defects (crystal surfaces, dislocations, vacancies, etc.) upon milling gives
rise to a genuine amorphous state, which is, in turn, characterized by chemical disorder.
Caron et al. (10, 80, 81) have studied the structural and thermodynamic changes of crys-
talline alpha-lactose in the course of its solid-state amorphization by milling. The results
revealed that, in the course of the milling process, the material cannot be described as a
biphasic system made of both perfect crystalline matter and genuine amorphous matter.
It appears to be constituted of a wide panel of structural states more or less disordered
and ranging from the crystalline state to the amorphous state. This conceptual difficulty
clearly emerges from the results of these authors, who have shown that very different
characterization techniques give rise to very different kinetics of amorphization (Table
I). Terada et al. (82) have shown that peak intensities of the X-ray powder diffraction
(XRPD) patterns of two polymorphs of terfenadine decreased with increasing grinding
times (Fig. 4).
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Table I. Differences in the time of amorphization depending on the
method of solid-state characterization
Indomethacin Lactose Trehalose
DSC 120 min 50 h 10 h
XRPD 30 min 1 h No data
ss-NMR 195 min 30 h 20 h
Adapted from refs. 10, 80, 81 with permission.
CHARACTERIZATION OF THE AMORPHOUS STATE
The strategy of characterizing amorphous solids differs from that for crystalline sol-
ids. Molecular-level structural elucidation, which is feasible for crystalline solids by dif-
fraction and spectroscopic methods, is less applicable to amorphous solids, and greater
emphasis is placed on structural mobility and changes. It is customary to characterize
amorphous material both below and above the glass temperature, i.e., both as a frozen
solid and a super-cooled viscous liquid. Thus effective characterization of amorphous
pharmaceutical products requires a multidisciplinary approach using complementary
analytical methods. To characterize pharmaceutical solids, we may use various techni-
ques, such as Raman spectroscopy (RS), Fourier transform infrared spectroscopy (FT-IR)
or solid state nuclear magnetic resonance (ss-NMR), which are primarily intramolecular
methods probing the sample at the molecular level. Intermolecular information is gai-
ned by directly employing techniques such as differential scanning calorimetry (DSC),
thermogravimetric analysis (TGA) and XRPD, which analyze the sample on the particu-
late level. Recently, tetrahertz pulsed spectroscopy (TPS), second harmonic generation
(SHG) and 14N nuclear quadrupole resonance (NQR) have been also used as spectros-
copy techniques to directly investigate particulate properties of solids (81, 83–85). Other
properties associated with the particulate level, such as morphology or size distribution,
can be characterized using microscopic techniques such as polarizing light microscopy
(PLM) and scanning electron microscopy (SEM) (84, 86). These methods offer several ty-
pes of information about the investigated substance (87, 88):
(i) Structure: The structure of amorphous solids is not random at the molecular le-
vel, but may possess short-range order, residual crystallinity, polymorphic states, and re-
gions of different density.
(ii) Thermodynamics: As mentioned before, amorphous solids present higher ener-
gy, entropy and free energy when compared to the crystalline state of the same material.
Excess properties are parameters included in some theoretical models of crystallization
and structural relaxation.
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Fig. 4. Change in XRPD patterns of terfenadine (form I and form II) by grinding. Adapted from ref.
82 with permission.
(iii) Changes: When exposed to the right conditions amorphous solids can crystal-
lize or undergo structural relaxation owning to instability compared to the correspond-
ing crystals and »equilibrium« glasses.
(iv) Multi-component systems: Many pharmaceutical formulations are formed by
either active substances and drug excipients or multiple active substances. One or more
of the components can be present in the amorphous state.
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Fig. 5. NMR spectra of a) 60-, 90-, 120-, 195-min cryo-milled samples of g-indomethacin and a-in-
domethacin; b) 195-, 345- and 420-min cryo-milled samples of g-indomethacin and quench cooled
amorphous indomethacin. The quench cooled sample and the cryo-milled samples with increasing
time of milling show much broader peaks, which is characteristic of amorphous substances (81).
Adapted from ref. 81 with permission.
ss-NMR
Recently, ss-NMR has been introduced to identify effects such as polymorphism,
intra- and inter-molecular hydrogen bonding and tautomerism and is now widely used
in conjunction with other analytical techniques (89). High-resolution 13C ss-NMR spec-
tra are obtained using proton decoupling and magic angle spinning (MAS) and sensitiv-
ity enhancement is achieved by cross-polarization (CP). 13C ss-NMR has the advantage
of being a nondestructive test method that provides information about the structure of
the material (90). Furthermore, one of the advantages of ss-NMR is that it is very sensi-
tive to minor conformational changes but is insensitive to particle size. In a ss-NMR stu-
dy of ranitidine hydrochloride, the authors showed that form II of the drug exhibits mo-
lecular disorder crystals and contains two tautomers, nitronic acid and enamine (91).
Molecular disorder was attributed to ranitidine hydrochloride solved intermolecular
bonding (89). For the characterization of organic substances, the remarkable sensitivity
of the 13C chemical shift to local modulations of electronic density has made this tech-
nique one of the best probes of conformational aspects. In particular, 13C CPMAS (cross
polarization magic angle spinning) appears to be well adapted for studying poly- (or
poorly) crystalline solids, revealing qualitative and quantitative features such as identifi-
cation of phases and structural changes in crystalline polymorphs of pharmaceutical
molecules (92–94). Recently, the development of proper analysis methods to measure rela-
tive amorphous and crystalline fractions has raised considerable interest (90, 95). Lefort
et al. (10) have shown, in a study of ball milling trehalose, that an NMR approach can be
readily implemented in many situations involving continuous transformations of pure
compounds and can still remain a successful method for estimating amorphous content
of a sample, even though DSC might fail at it (10). Furthermore, Bøtker et al. (81) utilized
ss-NMR to explain the influence of different times of cryo-milling on the amorphization
of indomethacin (Fig. 5).
X-ray powder diffraction
The principle behind XRPD experiments is the random orientation of crystals in a
substance. If powdered crystals are randomly oriented, then for all sets of planes some
of the crystals in the powder will be in the right orientation with respect to the X-ray
source to satisfy Bragg’s law for proper angle q. What follows is that at least a few of the
mineral grains in the powder will diffract for each of the planes during a scan through
angles q. The more finely ground the powder, the more likely it is that all orientations
are sufficiently present. The whole XRPD method is based on the fact that ideally every
possible crystalline orientation should be represented equally in a powdered sample.
Two main types of powder diffraction experiments are possible according to Smith: au-
tomated powder diffractometer experiments yielding (digital) computer output and De-
bye-Sherer experiments providing (analog) film output. The Debye-Sherer approach
uses a camera. A strip of film is wrapped around the powder sample so that diffracted
beams from a fixed X-ray source can be recorded for all values of q simultaneously. Dur-
ing the measurement, the powder diffractometer moves both the X-ray source and an
electronic detector through arcs of q values and sends to a computer periodic signals
proportional to the averaged diffracted X-ray intensity. Both experiments provide the in-
tensities for diffracted beams as a function of the diffraction angle q (or 2q). The acqui-
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red data is then processed by the Rietveld method in order to minimize the residual fun-
ction using a non-linear least squares algorithm. With that we can then refine the crystal
structure of a compound. XRPD is typically used to determine the occurrence of a non-
-crystalline solid form, since it can be determined by observing the loss of distinct XRPD
peaks characteristic of crystalline order, and the appearance of a general »halo« pattern
(1). There are, however, a number of different non-crystalline phases that can give broad
halos in the measured XRPD data, the most commonly observed of which are super-
-cooled liquids and glasses (96). Grinding or milling crystals can remove all traces of
crystalinity according to XRPD. Cryo-grinding studies provide an ideal experimental
approach to investigate the formation of amorphous material and the nature of the X-ray
diffraction response. The typical behavior observed when grinding a crystalline organic
material to produce amorphous material is that an increasing percentage of the crystal-
line material will collapse to amorphous as a function of grinding time. The amorphous
local packing generates broad halos in the XRPD pattern that are not correlated to the
crystalline peaks. If no significant change is observed in the crystalline diffraction peaks
upon grinding, the ground sample can be modeled as a phase separated binary mixture
of thermodynamic amorphous and crystalline materials. Although successive micro-
nization should eventually lead to an amorphous structure, a possibility exists that the
material has achieved a microcrystalline state, containing crystals so small that they pass
the detection of XRD. Johari et al. (97) used DSC to distinguish between amorphous and
microcrystalline states based on the presence or absence of glass transition when XRD
failed to do so. It should also be noted that materials ground to or exhibiting the same
X-ray amorphous pattern might crystallize at different times or to different crystalline
forms. This can be perceived as a lack of control, resulting in amorphous materials that
are not consistent. A better understanding of short-range and long-range interactions in
amorphous materials using atomic pairwise distributions can help explain and possibly
control the physical stability of materials. Data analysis of X-ray amorphous patterns
plays a significant role in addressing the primary regulatory concerns for drug commer-
cialization: understanding, stability and reproducibility (98).
Atomic pairwise distribution
The atomic pairwise distribution function (PDF) is a method used to analyze the lo-
cal structure based on the total scattering pattern from the crystalline, nanocrystalline,
quasi crystalline or amorphous materials (99, 100). The technique uses the Fourier trans-
formation of XRPD diffractograms to produce a trace in the coordinate system. The y-
-axis in the PDF graph corresponds to the probability of finding two atoms separated by
a distance plotted on the x-axis. In the material science community the PDF technique
has been used for several decades (101–105) and has more recently been applied by the
pharmaceutical community to study short- and long-range order amorphous glassy ma-
terials (106–111). It has been used in studies to investigate crystalline defects, help in the
crystal structure determination (106, 107, 110), characterization of polymer/drug sys-
tems (111–113) and the use of multivariate data analysis has alleviated the interpretation
of PDF (108, 111). It could be a possible route to gain a deeper insight into the degree of
disorder in a milled sample. This is due to the fact that PDF displays the probability of
finding two atoms separated by a given distance (99). Therefore, it could be expected
that with increasing disorder in the sample, the signal amplitude of the PDF trace would
316
T. Einfalt et al.: Methods of amorphization and investigation of the amorphous state, Acta Pharm. 63 (2013) 305–334.
be further reduced, until the highest possible disorder for a given cryo-milling process
has been achieved. Bøtker et al. (81) have found that PDF is capable of assessing the min-
imal cryo-milling time that facilitates the highest degree of disorder and stability in
cryo-milled samples of indomethacin.
Differential scanning calorimetry
Thermal methods have been used for amorphous content determination. DSC is a
method commonly used for investigation of phase behavior of pharmaceutical solids,
including quantification of the amorphous content (112). Depending on the instrument
type, measuring parameters and experimental conditions, there are several methodolo-
gies that can be employed to determine the latter. Among them are conventional DSC,
modulated temperature DSC (MTDSC) and hyper- or high-speed DSC (HSDSC) (113).
Conventional DSC is based on a linear heating rate. In temperature modulated DSC
(TMDSC), a small sinusoidal temperature modulation is applied to the sample in addi-
tion to the usual linear ramp. In the newest technique, hyper-DSC, controlled fast heat-
ing and cooling rates of 50 up to 500 °C min–1 are used (114). This significantly increases
measurement sensitivity because the increased scan rate leads to higher heat flow.
Whereas amorphous character can be difficult to detect in highly crystalline solids using
the conventional DSC technique, hyper DSC can show glass transitions with enhanced
sensitivity and a less time (114).
As mentioned before, amorphous materials exist as solid or liquid glasses like rub-
bers. The transition between these states is a second-order change phase, which occurs
at Tg (115). There are at least three ways to determine Tg. Standard Tg is the temperature
corresponding to the point on the heat flow curve where the specific heat change is 50 %
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Fig. 6. DSC curves of a freshly prepared amorphous form of indomethacin prepared by different
preparative techniques. Key: QC – quench cooled, SD – spray dried, BM – ball milled, CM –
cryo-milled. Adapted from ref. 8 with permission.
of the change in complete transition. This is the temperature at which heat capacity is
midway between the liquid and glassy state (116). Glass transition can be also regarded
as the inflection point of the DSC curve associated with glass transition. If a high relax-
ation peak follows glass transition, the inflection point of the DSC curve can differ from
the real inflection point of the glass transition. Fictive temperature refers to the point on
the enthalpy curve where the change of slope occurs (117). The enthalpy curve is the in-
tegral of the specific heat curve (Fig. 6). Fictive temperature is the intersection of the ex-
trapolated pre-transition and post-transition baselines on the enthalpy curve.
DCp is linearly proportional to the amorphous content in case that amorphous glas-
ses are in the same state. The largest change in specific heat is equal to the difference be-
tween crystalline and rubber states. When glass transition is used for the quantification
of amorphous content, there has to be a reference material. The starting point for the de-
velopment of this method is to ensure that the change in specific heat of a 100 % amor-
phous sample is reproducible. Many things influence DCp. Glasses are known to change
their properties when annealed below their glass transition temperature. The release of
relaxation enthalpy that follows glass transition corresponds to the enthalpy difference
between annealed and quenched (non-annealed) glass (118). Karmwar et al. (8) have
shown that DSC curves of amorphous forms of indomethacin prepared by quench cool-
ing and spray drying exhibit different Tg as shown in Fig. 6 and Table II.
Solution calorimetry
Few publications have utilized solution calorimetry to determine the extent of drug
and excipient crystallinity (119–123). This is a thermal technique in which the tempera-
ture change produced by a chemical or physical interaction during the mixing of two so-
lutions or of a solid or a liquid in a constant temperature environment is monitored as a
function of time (120). Studies suggest that solution calorimetry can be used to deter-
mine the amorphous content of a drug and excipient, when the solubility and dissolu-
tion rate of the compound in the chosen solvent are reasonably high. Typically, 100 %
crystalline and 100 % amorphous materials have been physically mixed to prepare sam-
ples of varying percent crystallinities, and a linear relationship between the heat of solu-
tion and the mass percent crystalline fraction present in the resulting mixture has been
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Table II. Thermal properties of amorphous forms of indomethacin prepared by different
preparative techniques (8)




QC 42.15 ± 1.16 0.50 ± 0.003 96.93 ± 1.02 1.03 ± 0.26
SD 41.25 ± 0.28 0.47 ± 0.28 73.59 ± 7.18 0.68 ± 0.31
BM (g-form) 39.23 ± 2.19 0.57 ± 0.03 62.14 ± 4.16 0.28 ± 0.09
CM (g-form) 40.27 ± 3.57 0.52 ± 0.16 60.84 ± 2.91 0.95 ± 0.84
BM (a-form) 37.92 ± 2.02 0.70 ± 0.09 70.16 ± 0.70 0.84 ± 0.43
Adapted from ref. 8 with permission.
demonstrated (120, 121). Harjunen et al. (124) have shown that this method can be also
used for assessment of the amorphous content of lactose that was not completely dis-
solved in a solvent. An excellent correlation was observed between the enthalpy of solu-
tion (DsolH) in water and the amorphous content of the samples, as shown in Fig. 7. Fur-
ther, there was also a linear correlation between the enthalpy accompanied with
addition of a lactose sample to an oversaturated aqueous solution (DsatH) and the amor-
phous content of the samples, as shown in Fig. 8. Interestingly, linear relationship was
observed between the DsatH and the DsolH of the samples. Therefore, solution calorime-
try may represent a rapid and simple method for determining the amorphous content
also in samples that are not completely dissolved in the solvent.
Density measurements
Solid density is a physical property, the value of which is frequently required in
both fundamental and applied pharmaceutics. True density may be obtained using pyc-
nometry, flotation density measurements, or from a single crystal structure. Flotation
density measurement, however, is not suitable for powder mixtures (125, 126). Crystal-
line materials in general have higher density than their amorphous counterparts becau-
se the atoms in the crystal lattice are located at a minimum possible distance from each
other. An increase in lattice disorder (decreasing crystallinity) usually results in an in-
crease in volume and therefore a decrease in density. Changes in crystalinity should the-
refore be accompanied by gradual, progressive changes in density (127). The degree of
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Fig. 7. Relationship between the DsolH and the amorphous content of: a) physical mixtures; b)
spray-dried samples. Mean values SD are shown (n = 4). Adapted from ref. 124 with permission.
crystallinity of a sample can be determined by Eq. (2) (r – obtained density, ra – density









Different density measurement techniques were used in literature to detect low lev-
els of the amorphous phase in crystalline pharmaceuticals (128) or to determine sample
crystallinity (1, 129). Therefore, density measurements can be also used as an alternative
technique to determine the solid state of pharmaceuticals. Salekigerhardt et al. (130) have
shown that an increase in density correlates with the disorder of solid sucrose (Fig. 9).
Gravimetric vapor sorption
Gravimetric vapor sorption is a technique used to determine the vapor sorption iso-
therms. Instruments measure how the mass of the sample changes as the vapor environ-
ment surrounding the sample is altered. An increase in mass is typically associated with
vapor sorption, whilst the occurence of mass decrease is attributed to vapor desorption.
Mixed saturated and dry carrier gas streams are used to control the vapour concentra-
tion around the sample. Dynamic vapor sorption has been previously used to character-
ize amorphous or partially amorphous systems (131). The principle behind it is that
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Fig. 8. Relationship between DsatH and the amorphous content of a) physical mixtures, b) spray-dried
samples. Mean values SD are shown (n = 4–8). Adapted from ref. 124 with permission.
amorphous materials typically have a higher surface area and vapour affinity than their
crystalline counterparts. More recently Vollenbroek et al. (132) have developed a method
which is based on gravimetric vapor sorption that allows determination of the amor-
phous lactose content over the range of 0.1–100 %. However, it must be noted that using
dynamic vapor sorption for determination of amorphous content may be flawed, becau-
se direct comparison of partially amorphous particles to wholly amorphous and wholly
crystalline systems may result in a significantly different outcome. This is due to the fact
that semicrystalline materials have different molecular mobility compared to wholly
amorphous or crystalline material (13).
Inverse gas cromatography
Inverse gas chromatography (IGC) is a vapor sorption technique in which powder
is packed in a column and known vapors (usually at infinitine dilution in a carrier gas)
are injected. It provides access to several physicochemical (surface and bulk) properties
of materials, including their surface energy, phase transitions, solubility parameter,
crystallinity, and acid-base characteristics (133, 134). It has been also used to detect sur-
face energy changes caused by milling (135). It was found for sucrose that milling does
not influence the crystal structure particles, but only the particle size and relative expo-
sure of specific crystal planes. From the retention times of the probes it is possible to as-
sess the surface nature of the material in the column (130). It is expected that this vapor
sorption approach is also able to detect small amounts of amorphous content (88). Pla-
ninsek et al. (136) have shown that IGC is an efficient method for the quantification of
the fraction of amorphous surface of milled indomethacin. It was shown that combina-
tion of IGC with DSC enables not only quantification but also localization of structural
changes of milled indomethacin. Namely, it enables differentiation between the trans-
formed structure at the surface of particles and transformations of the bulk region.
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Fig. 9. Density vs. percent disorder for mixtures of amorphous and crystalline sucrose. Adapted from
ref. 130 with permission.
MID infrared spectroscopy
Middle (MID) infrared methods can reflect significant spectral differences between
crystalline and amorphous phases and are hence used to quantify the crystalline con-
tent, since the intensity of the vibrational bands is directly proportional to the concentra-
tion of the concerned phase. Amorphous form of a given drug give rise to IR spectra
that differs from its crystalline counterparts. The origin of these differences relates to
both the wider range of conformations typically present in an amorphous solid, which
normally leads to the presence of broader peaks relative to those found in the crystalline
spectrum, as well as to differences in intermolecular interactions (1). Infrared procedures
for measuring the degree of crystallinity are based upon the measurement of the inten-
sity of a peak, characteristic of the crystalline state with reference to a peak that is inde-
pendent of the crystal state of the substance. Nakai et al. (75) have shown that it is possi-
ble to study the effect of grinding on the crystallinity of microcrystalline cellulose (MCC)
using the infrared technique and similarly Otsuka and his coworkers (137) also studied
the effect of grinding on the crystallinity of cephalothin. MID-IR has also been found to
be extremely useful to study amorphous solid dispersions (138). A study by Tang et al.
(139) used FT-IR spectroscopy to characterize the differences between crystalline and the
amorphous phases of dihydropyridine calcium channel blockers. For all compounds, the
amorphous and crystalline samples gave rise to different spectra.
Near infrared spectroscopy
Near infrared spectroscopy (NIR) is a noninvasive technique, which requires no
sample preparation; it is also non-destructive, enabling complete sample retrieval espe-
cially if used with the diffuse reflectance option. In addition, further quantitative infor-
mation can be extracted from the data using chemoinfometrics, where the collected data
is processed by means of statistical and applied mathematical techniques. Quantification
of crystallinity is usually performed using the first (140) or second derivate spectra (95,
141, 142). Physical and chemical information such as polymorphism (143) and mutaro-
tation (144) may be obtained. Buckton et al. (145) have shown that it is possible to moni-
tor the crystallization of amorphous lactose in real time through examination of NIR
spectra at certain wavelengths. Moreover, Hogan et al. (144) have shown that it is possi-
ble to quantify the amorphous content of lactose with NIR. Luner et al. (141) used the
technique to determine the crystallinity of several pharmaceuticals, including indome-
thacin, lactose, ampicillin and sucrose. NIR was also used by Otsuka et al. (146) to moni-
tor the stability of amorphous indomethacin in humidity controlled 96-well plates. Fur-
thermore, Otsuka et al. (147) have shown that the crystallinity of unknown samples
obtained by FT-NIR chemoinfometrical spectrometry was consistent with that obtained
by conventional X-ray powder diffractometry and was more accurate (Fig. 10). Accord-
ing to the change in NIR absorbance of indomethacin, the solid structure of amorphous
indomethacin was significantly different from that of the crystalline form.
Raman spectroscopy
Raman spectroscopy is a spectroscopic method used to observe vibrational, rotatio-
nal, and other low-frequency modes in a system. It probes properties of the molecule it-
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self, and changes in the solid-state properties of a substance are inferred from changes in
the molecular conformation and molecular environment. This is due to the different pack-
ing conditions of the molecules in different solid forms. Differences can then be seen as
subtle changes in the peak positions and intensities in the Raman spectra (148). It has been
recently used in various studies for means of differentiation between differently prepared
amorphous forms of the same substace. Karmwar et al. (8, 149) have shown that this is a
suitable method for the detection of differences between differently prepared amorphous
forms of indomethacin and simvastatin. Similarly Zimper et al. (79) have shown that
Raman spectroscopy combined with multivariate analysis can detect and quantify disor-
der in a substance. Nevertheless, the authors point out that Raman spectroscopy, as a mo-
lecular level technique, is sensitive to the near order of solid materials and therefore could
'underestimate' the degree of disorder if the material remains near the range ordered to a
certain extent (i.e., exists as a dimer) in the amorphous state. However, in contrast to the
findings of the previous authors, Boetker et al. (150) have found that it is unable to distin-
guish between differently prepared samples of amlopidine.
Dissolution tests
As the molecular mobility of the amorphous form is higher compared to the equiva-
lent crystalline form, it may have an enhanced dissolution rate. This difference can be
used to estimate the degree of amorphous content in a given sample. Although the
amorphous form will have a higher dissolution rate because of high-surface free energy,
there is an inherent risk of devitrification in the dissolution fluid (151), rendering disso-
lution tests useless for characterization of the solid state. However, the amount dissol-
ved has been used to quantify crystallinity in the case of amorphous solid dispersions.
(152). The main problem encountered in this technique is the effect of surface area; if not
controlled stringently, it can significantly affect the results. To control the surface area,
the powder is compressed. This may lead to probable phase changes. Also, the dissolu-
tion medium needs to be carefully selected as the components of the medium can influ-
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Fig. 10. Relation between predicted crystallinity of unknown indomethacin samples obtained by
the conventional X-ray powder and FT-NIR method. Bars represent standard deviation. Adapted
from ref. 147 with permission.
ence the final outcome (88). Care must be taken when using this method if the transfor-
mation process includes extensive crystal defect formation, which is especially expected
in the early stages of amorphization due to mechanical milling. Because the dissolution
depends on solvent accessible surface and surface energy, crystal defect formation and
increased surface could lead to false results.
Microcalorimetry
Microcalorimetry is a technique that has attracted much interest among pharmaceu-
tical researchers as it can be used for various studies of preformulation. One among the
possible uses of microcalorimetry is also assessment of the amorphous content (153–
156). Determination of the amorphous content by microcalorimetry is based on the fact
that conversion from the amorphous to the crystalline form is detected as an exothermic
heat flow. The area under the exothermic peak is then proportional to the amorphous
content. In some cases, the sensitivity of the calorimetric approach was even proven to
be better than XRPD. Furthermore, one of the advantages of the technique is that it al-
lows to measure the »real time« response in the calorimeter monitoring recrystallization
of the amorphous substance (154).
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Fig. 11. Terahertz spectra of amorphous samples derived from a- and g-indomethacin forms using
different preparation techniques: a) powder samples prepared from a-indomethacin; b) powder
samples prepared form g -indomethacin. CA a-indomethacin, CG – g -indomethacin, AA – ground
amorphous a-indomethacin, AQ – fast cooled amorphous indomethacin, AG – ground amorphous
g -indomethacin, AS – slowly cooled indomethacin. Adapted from ref. (9) with permission.
Terahertz spectroscopy
Detection of terahertz radiation waves (THz), which have a frequency between 0.1
and 10 THz, is potentially very useful in probing intermolecular-level long range with-
out sample contact and destructive treatment when characterizing solid-state materials,
since it can induce low frequency bond vibrations, crystalline phonon vibrations hydro-
gen-bonding stretches, and torsion vibrations (153). A recent study by Otsuka et al. (9)
has shown that THz spectroscopy is suited as a discrimination method between differ-
ent amorphous states of pharmaceuticals called »poly-amorphous solids«. Fig. 11 shows
the THz spectra of polymorphic crystalline forms and the amorphous solids of indome-
thacin obtained by the transmittance method.
CONCLUSIONS
Due to their higher solubility and bioavailability compared to the crystalline state,
amorphous solids have received a lot of attention in the past decades. In this review, we
have presented the possible methods of preparation of amorphous solids and their chara-
cterization. We elaborated on the background mechanisms involved in the process of
amorphization, with the emphasis on amorphization through milling. The wide array of
solid-state characterization techniques that can be utilized to investigate the different
properties of the amorphous forms of substances prepared by various methods is also
presented, since amorphous forms prepared by different means of amorphization often
exhibit differences in stability and solubility. Moreover, differences can be also screened
by commonly used methods of solid state characterization. We concluded that a multi-
variate visualization combined with complementing spectroscopic characterization of-
fers an effective tool to screen for differences in amorphous samples.
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